Abstract
Background
Food–drug interactions can produce negative effects in the safety and efficacy of drug therapy, as well as in the nutritional status of the patient. However, the data commonly provided to the prescriber about possible nutrient–pharmacological compound interactions and the recommendations for their prevention are often scarce. The summary of product characteristics (SmPC) of a proprietary medicinal product, as authorised by the health authorities in Europe, is usually the main source of information for the health professional. Therefore, the SmPC can be a useful tool to prevent or reduce food–drug interactions and, as a consequence, improve the therapeutical approach.
Objective
The aim of this study was to assess the information about food–drug interactions with potential clinical relevance as it is described in the SmPCs of the authorised medicinal products in a European Union country (Spain).
Methods
A bibliographical search of food–drug interactions, including nutrients and alcohol, was carried out. The adequate information to be included in the SmPC was defined in accordance with the European Recommendations in this field. The SmPCs of the medicinal products containing selected active substances were examined with emphasis on food–drug interactions.
Results
It was found that, frequently, the information concerning food–drug interactions as is mentioned in the SmPC of the authorised medicinal products in Spain does not fulfil the current recommendations, both in quantity and quality. Indeed, the available data reveal that the food–drug information is only mentioned in 72.7% of all SmPC where it should be and it was only found in the specific section for interactions in 36.0% of all cases. The description and agreement with recommendations for each SmPC item ranged between 4.2% and 36.0% and between 31.8% and 49.0%, respectively. Some related factors, such as the clinical relevance of the interaction, the existence of an authorised SmPC and the registration procedure followed, influence the information characteristics concerning food–drug interactions.
Conclusion
The SmPC is a suboptimal source of information for food–drug interactions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Guédon-Moreau L, Ducrocq D, Duc MF, et al. (2004) Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 59:899–904
Williams L, Davis JA, Lowenthal DT (1993) The influence of food on the absorption and metabolism of drugs. Med Clin North Am 77:815–829
Sorensen JM (2002) Herb-drug, food–drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 8:293–308
Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG (1995) Drug-food interactions in clinical practice. J Fam Pract 40:376–384
Anderson KE, Greenblatt DJ (2002) Assessing and managing drug-nutrient interactions. J Am Pharm Assoc (Wash) 42(suppl 1):S28–S29
Kirk JK (1995) Significant drug-nutrient interactions. Am Fam Physician 51:1175–1182
Couris RR, Tataronis Gr, Dallal GE, Blumberg JB, Dwyer JT (2000) Assessment of healthcare professionals’ knowledge about warfarin–vitamin K drug nutrient interactions. J Am Coll Nutr 19:439–445
Lasswell AB, DeForge BR, Sobal J, Muncie HL Jr, Michocki R (1995) Family medicine residents’ knowledge and attitudes about nutrient interactions. J Am Coll Nutr 14:137–143
Guideline on Summary of product characteristics (The rules governing medicinal products in the European Union, The Notice to Applicants), 1999. Pharmaceutical legislation. Eudralex. European Commission. (http://pharmacos.eudra.org/F2/)
Note for guidance on the investigation of drug interactions. Committee for proprietary medicinal products, 1997. (http://www.emea.eu.int)
Mariné A, Vidal MC, Codony R (1993) Interacciones entre fármacos y alimentos. In: Nutrición y dietética. Aspectos sanitarios. Consejo General de Colegios Oficiales de Farmacéuticos. Madrid 2:902–957
Griffin JP, D’Arcy PF (1997) Nutrient–drug interactions. In: A manual of adverse drug interactions, 5th edn. Elsevier, Amsterdam
Chan LN (2002) Drug–nutrient interaction in clinical nutrition. Curr Opin Clin Nutr Metab Care 5:327–332
Schmidt LE, Dalhoff K (2002) Food–drug interactions. Drugs 62:1481–1502
Montoro JB, Salgado A (1999) Interacciones fármacos-alimentos. Ed. Rubes Editorial. Barcelona
Wolfgang GH, Johnson DE (2002) Web resources for drug toxicity. Toxicology 173:67–74
Jiménez NV, Merino M, Ordovás JP, Casabó V (1999) Interacciones entre medicamentos y alimentos: bases farmacoterapéuticas. 1° ed. Ed. Nutricia. Madrid
García T (2001) Las interacciones con alimentos no se tratan bien en los prospectos. Correo Farmacéutico, week from 19–25 of November
García-Gómez C, Poveda JL, Martínez H, Valladolid A, Hernández M (2001) Análisis de las pautas de coadministración de alimentos con medicamentos. Nutr Hosp 16:12
Bailey DG, Malcolm J, Arnold O, Spence JD (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101–110
Laitinen K, Patronene A, Harju P et al (2000) Timing of food intake has a marked effect on the bioavailability of clodronate. Bone 27:293–296
Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41–57
San Miguel MT, Vargas E, Martínez JA (2004) Interacciones entre medicamentos y alimentos: aspectos actuales. An R Acad Nac Farm 70:147–179
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
San Miguel, M.T., Martínez, J.A. & Vargas, E. Food–drug interactions in the summary of product characteristics of proprietary medicinal products. Eur J Clin Pharmacol 61, 77–83 (2005). https://doi.org/10.1007/s00228-004-0846-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-004-0846-9